Thera-SAbDab

VONLEROLIZUMAB

>   Structural Summary
TherapeuticVonlerolizumab
TargetTNFRSF4
Heavy ChainEVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPPTFGQGTKVEIK
100% seqID Fv Structure6ogx [Fvs: CD], 6okn [Fvs: AB, CD]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Phase-II
Estimated Status (August '23)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2015
INN Year Recommended2017
Companies InvolvedGenentech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours, Urogenital cancer
NotesVonlerolizumab is the new name for Pogalizumab (PL116)

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy